Abstract 264P
Background
Cancer-related cognitive impairment (CRCI), affecting up to 80% of breast cancer (BC) patients, manifests in various cognitive domains such as learning, memory, and concentration. The hippocampus, crucial for these cognitive processes and known to retain its neurogenesis capacity throughout adulthood, is susceptible to morphological alterations due to BC treatment. Recent research highlights the link between physical exercise and neurogenesis. This study aims to investigate CRCI and the potential effects of high-intensity interval training (HIIT) on learning, memory, and concentration function, as well as brain morphology in BC patients undergoing treatment.
Methods
This randomized (1:1) controlled trial allocated early-stage BC patients to either a HIIT intervention group (IG) or a control group (CG). The intervention involved a 12-month supervised HIIT program tailored through cardio-pulmonary exercise testing. Learning, memory, and concentration function were assessed using the California Verbal Learning Test (CVLT) alongside the Wechsler Memory Scale (WMS). Hippocampal volume was evaluated with MRI-based free surfer analysis. Assessments were conducted at baseline and after 12 months.
Results
A total of 69 patients (mean age 50.67 years, SD 10.55; 98.5% female) were recruited. The analysis showed no statistically significant changes in total hippocampal volume in either group (IG: p = 0.25 and p = 0.39; CG: p = 0.25 and p = 0.33). Similarly, no significant changes were observed in the CVLT scores for both groups (IG: p = 0.102; CG: p = 0.059). However, compared to the CG, the IG exhibited significant improvements in the WMS (p < 0.05).
Conclusions
Assessing CRCI in BC patients is challenging. Despite a multimodal approach, we couldn't objectify structural or functional adverse effects on specific cognitive subdomains. Although HIIT exercise during chemotherapy didn't notably impact learning and memory, it did enhance concentration over time. This might suggest that cognitive function in BC patients benefits from exercising.
Clinical trial identification
NCT04789187. Registered on 09 March 2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Verein zur Forschungsförderung der Krebshilfe OÖ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
292P - Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2– early breast cancer (EBC) from US electronic health records (EHR)
Presenter: Komal Jhaveri
Session: Poster session 14
293P - Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
Presenter: Luc Cabel
Session: Poster session 14
294P - Survival outcomes according to tumor-infiltrating lymphocytes and 21-gene recurrence score in ER+HER2- breast cancer
Presenter: Sung Gwe Ahn
Session: Poster session 14
295P - Long-term clinical outcomes and treatment strategy considerations by ER expression level in breast cancer
Presenter: Yumi Wanifuchi-Endo
Session: Poster session 14
296P - Investigating survival by breast cancer molecular subtype in Australia: A population-based study
Presenter: Larissa Vaz-Goncalves
Session: Poster session 14
297P - Real-world data on prognostication of early stage breast cancer patients using CanAssist Breast- first immunohistochemistry based prognostic test developed and validated on Asians
Presenter: Vashista Maniar
Session: Poster session 14
Resources:
Abstract
298P - Enhancing prognostic accuracy for breast adenoid cystic carcinoma using machine learning models
Presenter: Sakhr Alshwayyat
Session: Poster session 14
Resources:
Abstract
299P - Characterization and clinical outcomes of low hormonal receptor positive / HER2 negative early breast cancer
Presenter: Jitnarong Karnmanee
Session: Poster session 14
300P - Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up
Presenter: Julia Tutzauer
Session: Poster session 14
301P - Changes in lipid-levels following aromatase inhibitor treatment in early postmenopausal breast cancer
Presenter: Marie Lund
Session: Poster session 14